Ubs Oconnor LLC Replimune Group, Inc. Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 30,000 shares of REPL stock, worth $342,000. This represents 0.02% of its overall portfolio holdings.

Number of Shares

30,000

Holding current value

$342,000

% of portfolio

0.02%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$8.09 - $11.23 $107,710 - $149,516	-13,314 Reduced 6.45%	193,122 $2.12 Million
Q2 2024 Aug 14, 2024	BUY	$5.01 - $9.46 $568,359 - $1.07 Million	113,445 Added 122.0%	206,436 $1.86 Million
Q1 2024 May 15, 2024	SELL	$6.87 - $9.31 $48,151 - $65,253	-7,009 Reduced 7.01%	92,991 $759,000
Q4 2023 Feb 14, 2024	BUY	$6.75 - $16.18 $675,000 - $1.62 Million	100,000 New	100,000 $843,000
Q1 2023 May 15, 2023	BUY	$17.48 - $29.09 $690,460 - $1.15 Million	39,500 New	39,500 $697,000
Q2 2019 Aug 14, 2019	SELL	$12.51 - $17.28 $330,038 - $455,880	-26,382 Reduced 48.33%	28,200 $0
Q1 2019 May 13, 2019	SELL	$10.26 - $16.24 $143,116 - $226,531	-13,949 Reduced 20.35%	54,582 $0
Q4 2018 Feb 15, 2019	BUY	$9.97 - $15.57 $158,184 - $247,033	15,866 Added 30.13%	68,531 $685,000
Q3 2018 Nov 14, 2018	BUY	$14.99 - $22.14 $789,448 - $1.17 Million	52,665 New	52,665 $0

Others Institutions Holding REPL

# of Institutions

150

Shares Held

68.3M

Call Options Held

52.3K

Put Options Held

80.3K

Baker Bros. Advisors LP New York, NY

11M
Shares

$126 Million
1.3% of portfolio
Price T Rowe Associates Inc Baltimore, MD

9.88M
Shares

$113 Million
0.01% of portfolio
Fcpm Iii Services B.V. Naarden, P7

4.87M
Shares

$55.5 Million
9.16% of portfolio
Redmile Group, LLC San Francisco, CA

4.78M
Shares

$54.5 Million
3.43% of portfolio
Black Rock Inc. New York, NY

4.71M
Shares

$53.7 Million
0.0% of portfolio

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $562M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account